Jazz Pharmaceuticals Announces Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Jazz Pharmaceuticals (JAZZ) PT Cut to $170 at Canaccord Genuity
November 10, 2015 10:20 AM ESTJazz reported a slightly disappointing Q3 with revenue of $340.9M, missing consensus by $7M. Non-GAAP EPS for the Q was $2.52, below consensus of $2.56.
Full-year guidance was narrowed slightly but it's more toward the lower end of the range given in Q2. Canaccord Genuity analyst, Corey Davis, noted that... More
Delays at the central pharmacy Negatively Hit Jazz Pharmaceuticals (JAZZ); Piper Jaffray Cuts Price Target to $186
November 10, 2015 9:51 AM ESTPiper Jaffray reiterated an Overweight rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and cut the price target to $186.00 (from $208.00), following the company's 3Q earnings report. Jazz reported non-GAAP EPS of $2.52 on revenues of $341M, largely in-line with the Street estimates of $2.56 and $348M, respectively. Xyrem sales totaled $243M, up from $204M in 3Q14, with annual volume... More
Jazz Pharmaceuticals (JAZZ) Reports Topline Miss Related to Delays in Xyrem Refills; Leerink Partners Cuts Price Target to $187
November 10, 2015 8:42 AM ESTLeerink Partners maintained an Outperform rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and cut the price target to $187.00 (from $220.00), following the company's 3Q earnings report. JAZZs update included a modest topline miss driven by slower patient volume growth as the company experienced delays in Xyrem refills.
Analyst Jason... More
Mizuho Securities Downgrades Jazz Pharmaceuticals (JAZZ) to Neutral
November 10, 2015 6:31 AM ESTMizuho Securities downgraded Jazz Pharmaceuticals (NASDAQ: JAZZ) from Outperform to Neutral with a price target of $140.00 (from $164.00) on valuation.
Analyst Irina Koffler commented, "We are downgrading Jazz to NEUTRAL from BUY and lowering our PT from $164 to $140 on revised valuation methodology.... More
Jazz Pharmaceuticals (JAZZ) Misses Q3 EPS by 4c, Updates FY Guidance
November 9, 2015 4:10 PM ESTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $2.52, $0.04 worse than the analyst estimate of $2.56. Revenue for the quarter came in at $340.9 million versus the consensus estimate of $348.15 million.
Jazz Pharmaceuticals sees FY2015 EPS of $9.45-$9.60, versus the consensus of $9.67. Jazz Pharmaceuticals sees FY2015... More
